Table 2.
Factors Associated with Poor OS After TACE-CRA for HCC According to Univariate and Multivariate Analysis
| Factor | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (years) | 1.932 (1.427, 5.336) | 0.007 | 2.382 (1.884, 7.823) | 0.002 |
| <65 | 45 | 45 | ||
| ≥65 | 41 | 41 | ||
| Gender | 1.478 (0.038, 2.362) | 0.246 | … | … |
| Male | 68 | 68 | ||
| Female | 18 | 18 | ||
| Hepatitis B surface antigen | 2.512 (0.368, 4.447) | 0.442 | … | … |
| Positive | 66 | 66 | ||
| Negative | 20 | 20 | ||
| Tumor size (cm) | 1.916 (1.562, 3.274) | 0.012 | … | … |
| <7 | 70 | 70 | ||
| ≥7 | 16 | 16 | ||
| Tumor number | 2.317 (0.835, 5.078) | 0.206 | … | … |
| Single | 37 | 37 | ||
| Multiple | 49 | 49 | ||
| α-fetoprotein level (ng/mL) | 1.884 (1.271, 2.793) | 0.445 | … | … |
| ≤20 | 44 | 44 | ||
| >20 | 42 | 42 | ||
| ALT level (U/L) | 2.872 (0.723, 4.382) | 0.568 | … | … |
| ≤40 | 40 | 40 | ||
| >40 | 46 | 46 | ||
| AST level (U/L) | 1.328 (0.273, 2.944) | 0.672 | … | … |
| ≤40 | 38 | 38 | ||
| >40 | 48 | 48 | ||
| Platelet count (/mm3) | 3.235 (0.556, 7.834) | 0.512 | … | … |
| ≤105 | 12 | 12 | … | |
| >105 | 74 | 74 | ||
| INR | 2.892 (1.457, 5.823) | 0.445 | … | … |
| >1.1 | 64 | 64 | ||
| ≤1.1 | 22 | 22 | ||
| CRA session | 1.345 (0.493, 3.665) | 0.563 | … | … |
| ≤3 | 48 | 48 | ||
| >3 | 12 | 12 | ||
| TACE session | 1.877 (0.632, 3.488) | 0.346 | … | … |
| ≤3 | 62 | 62 | ||
| >3 | 5 | 5 | ||
| Child–Pugh grade | 1.012 (0.332, 3.192) | 0.093 | … | … |
| A | 80 | 80 | ||
| B | 6 | 6 | ||
| ALBI grade | 3.398 (1.950, 6.058) | 0.001 | 3.398 (1.950, 6.058) | <0.001 |
| 1 | 59 | 59 | ||
| 2–3 | 27 | 27 | ||
| PALBI grade | 2.734 (1.251, 5.547) | 0.002 | … | … |
| 1 | 44 | 44 | ||
| 2–3 | 42 | 42 | ||
Note: Data in parentheses are 95% confidence intervals. Variables were analyzed by a univariate model of Cox Proportional Hazard Test; those with a P-value < 0.05 were showed here and were forwarded to the multivariate analysis.
Abbreviations: OS, overall survival; HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; CRA, cryoablation; ALT, alanine aminotransferase; AST, aspartate aminotransferase (AST); INR, international normalized ratio; ALBI, albumin–bilirubin; PALBI, platelet-albumin–bilirubin.